VYGR insider transaction filings
Voyager Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-11. Screen VYGR transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | MACKEY CATHERINE J — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Hyman Steven — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Vitale Nancy — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Onyia Jude — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Colon Grace — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Higgins Michael J — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | PIERCE GLENN — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | SCANGOS GEORGE A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Shiferman Gregory L. — SVP and General Counsel | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-04-03 | 4 | Sandrock Alfred — President and CEO, Director | Sale (S): 11,511 @ $3.87 | EDGAR |
| 2026-02-26 | 4 | Swartz Robin — COO & CBO | Sale (S): 6,458 @ $3.77 | EDGAR |
| 2026-02-26 | 4 | Jorgensen Nathan D. — Chief Financial Officer | Sale (S): 4,668 @ $3.77 | EDGAR |
| 2026-02-26 | 4 | Carter Todd Alfred — Chief Scientific Officer | Sale (S): 4,174 @ $3.76 | EDGAR |
| 2026-02-26 | 4 | Sandrock Alfred — President and CEO, Director | Sale (S): 14,197 @ $3.79 | EDGAR |
| 2026-02-20 | 4 | Swartz Robin — COO & CBO | Sale (S): 3,882 @ $3.44 | EDGAR |
| 2026-02-20 | 4 | Carter Todd Alfred — Chief Scientific Officer | Sale (S): 3,301 @ $3.44 | EDGAR |
| 2026-02-20 | 4 | Sandrock Alfred — President and CEO, Director | Sale (S): 11,732 @ $3.41 | EDGAR |
| 2026-02-11 | 4 | Swartz Robin — COO & CBO | Sale (S): 4,569 @ $3.85 | EDGAR |
| 2026-02-11 | 4 | Carter Todd Alfred — Chief Scientific Officer | Sale (S): 3,525 @ $3.85 | EDGAR |
| 2026-02-11 | 4 | Sandrock Alfred — President and CEO, Director | Sale (S): 12,192 @ $3.78 | EDGAR |
| 2026-02-10 | 4 | Ferguson Toby — Chief Medical Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Carter Todd Alfred — Chief Scientific Officer | Grant/award (A): 33,000 @ $0 · Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Swartz Robin — COO & CBO | Grant/award (A): 45,000 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Jorgensen Nathan D. — Chief Financial Officer | Grant/award (A): 32,250 @ $0 · Grant/award (A): 150,500 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Sandrock Alfred — President and CEO, Director | Grant/award (A): 86,250 @ $0 · Grant/award (A): 402,500 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Shiferman Gregory L. — SVP and General Counsel | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | Jorgensen Nathan D. — Chief Financial Officer | Sale (S): 7,666 @ $4.78 | EDGAR |
| 2025-08-20 | 4 | Ferguson Toby — Chief Medical Officer | Sale (S): 19,000 @ $3.73 | EDGAR |
| 2025-06-04 | 4 | Vitale Nancy — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Onyia Jude — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | MACKEY CATHERINE J — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Hyman Steven — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Colon Grace — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Higgins Michael J — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | PIERCE GLENN — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | SCANGOS GEORGE A — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Ferguson Toby — Chief Medical Officer | Sale (S): 10,086 @ $3.43 | EDGAR |
| 2025-04-04 | 4 | Sandrock Alfred — President and CEO, Director | Sale (S): 10,885 @ $3.43 | EDGAR |
| 2025-02-24 | 4 | Carter Todd Alfred — Chief Scientific Officer | Sale (S): 3,305 @ $4.26 · Grant/award (A): 46,000 @ $0 · Grant/award (A): 92,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Swartz Robin — COO & CBO | Sale (S): 3,894 @ $4.25 · Grant/award (A): 71,250 @ $0 · Grant/award (A): 142,500 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Fahey Sandell Jacquelyn — Chief Legal Officer | Grant/award (A): 41,500 @ $0 · Grant/award (A): 83,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Ferguson Toby — Chief Medical Officer | Grant/award (A): 63,000 @ $0 · Grant/award (A): 126,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Jorgensen Nathan D. — Chief Financial Officer | Grant/award (A): 51,500 @ $0 · Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Sandrock Alfred — President and CEO, Director | Sale (S): 11,702 @ $4.24 · Grant/award (A): 145,000 @ $0 · Grant/award (A): 290,000 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Carter Todd Alfred — Chief Scientific Officer | Sale (S): 5,413 @ $4.45 | EDGAR |
| 2025-02-12 | 4 | Swartz Robin — COO & CBO | Sale (S): 6,950 @ $4.45 | EDGAR |
| 2025-02-12 | 4 | Fahey Sandell Jacquelyn — Chief Legal Officer | Sale (S): 4,358 @ $4.45 | EDGAR |
| 2025-02-12 | 4 | Sandrock Alfred — President & CEO | Sale (S): 16,644 @ $4.45 | EDGAR |
Recent 8-K events — Voyager Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-01-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VYGR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →